Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Baiyunshan announced that Baiyunshan Bio, which is within its consolidated reporting scope, has received a Certificate of Drug Registration for its freeze-dried human rabies vaccine, Vero cells, issued by the Pharmaceutical Administration Bureau of the Macau Special Administrative Region Government. The vaccine will be authorized for sale in Macau by GPHL International Macau. Previously, the product obtained a Drug Registration Certificate from the National Medical Products Administration in December 2025, with cumulative R&D investment of approximately 205 million yuan.

Jiamei Packaging released its 2026 interim report, with first-half operating revenue of 1.371 billion yuan, up 9.12% year on year, and net profit attributable to the parent of 70.3759 million yuan, up 256.49% year on year. Filling business revenue was 256 million yuan, a sharp increase of 52.49% year on year, three-piece can business revenue was 659 million yuan, and two-piece can revenue was 297 million yuan, up 18.42%. The company recently won the bid for Guangzhou Baiyunshan Pharmaceutical's tin can procurement project, entering the pharmaceutical and health packaging supply chain, and launched an interim dividend plan of 0.40 yuan in cash per 10 shares, with total cash distribution of about 43.94 million yuan, accounting for about 62% of first-half net profit attributable to the parent. In addition, the company completed a change of control in the first half of the year, completed an early re-election of the board of directors in July, and formally proposed a 'second growth curve' strategic concept, focusing on strategic emerging industries and industrial chain integration opportunities.

Baiyunshan's wholly-owned subsidiary Mingxing Pharmaceutical has passed the generic drug quality and efficacy consistency evaluation for its norepinephrine bitartrate injection. The drug, with a specification of 1ml:2mg, was approved for marketing in 1982 and is used for blood pressure control in certain acute hypotensive states. Mingxing Pharmaceutical submitted its consistency evaluation application on April 16, 2025, and it was accepted on April 30. According to Menet data, domestic sales of this drug in 2025 were approximately 769 million yuan, with major manufacturers including Grand Pharmaceutical, Hefei Yifan Biotech, and Tianjin Jinyao Pharmaceutical. Mingxing Pharmaceutical's R&D investment for this consistency evaluation was approximately 1.2557 million yuan.

Baiyunshan announced that its controlling subsidiary Tianxin Pharmaceutical's Citicoline Sodium Injection in the 2ml:0.25g specification has passed the generic drug quality and efficacy consistency evaluation. At the same time, it received approval to add a new 4ml:0.5g specification, which is deemed to have passed the consistency evaluation. The drug is used for consciousness disorders following acute craniocerebral trauma and brain surgery.

Baiyunshan announced that its branch, Baiyunshan Pharmaceutical General Factory, received a Drug Registration Certificate issued by the Macau Pharmaceutical Administration Bureau on July 20, 2026, for cephalexin capsules. The product is a prescription drug indicated for respiratory tract infections, urinary tract infections, and skin and soft tissue infections caused by susceptible bacteria. Baiyunshan Pharmaceutical General Factory has authorized GPHL International Macau to distribute the product in Macau.

Guangzhou Baiyunshan Pharmaceutical Holdings announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical, has had its dexamethasone sodium phosphate injection, one milliliter to five milligrams, pass the generic drug quality and efficacy consistency evaluation. The drug is mainly used for allergic and autoimmune inflammatory diseases. Tianxin Pharmaceutical submitted the application in December 2024. According to Menet data, in 2025, sales of this specification product in domestic urban and county-level public hospitals, as well as urban and online pharmacies, reached 236 million yuan. The company invested approximately 3.17 million yuan in research and development for this project. In 2025, Tianxin Pharmaceutical's sales revenue from this product was 2.84 million yuan. The company stated that passing the consistency evaluation will help enhance the product's market competitiveness, but there is uncertainty in production and sales.